TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer (Q36145430)

12 August 2017

TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer (English)

1 reference

triple-negative breast cancer

12 August 2017

1 reference

1 reference

1 reference

19

1 reference

12 August 2017

2

Hope S Rugo

1 reference

12 August 2017

7

Minetta C Liu

1 reference

12 August 2017

20

Eric P Winer

1 reference

12 August 2017

18

Katherine A Hoadley

1 reference

12 August 2017

12

Timothy J Hobday

1 reference

12 August 2017

Lisa A Carey

1

1 reference

12 August 2017

P Kelly Marcom

3

1 reference

12 August 2017

Erica L Mayer

4

1 reference

12 August 2017

Francisco J Esteva

5

1 reference

12 August 2017

Cynthia X Ma

6

1 reference

12 August 2017

Anna Maria Storniolo

8

1 reference

12 August 2017

Mothaffar F Rimawi

9

1 reference

12 August 2017

Andres Forero-Torres

10

1 reference

12 August 2017

Antonio C Wolff

11

1 reference

12 August 2017

Anastasia Ivanova

13

1 reference

12 August 2017

Wing-Keung Chiu

14

1 reference

12 August 2017

Madlyn Ferraro

15

1 reference

12 August 2017

Emily Burrows

16

1 reference

12 August 2017

Philip S Bernard

17

1 reference

12 August 2017

language of work or name

English

0 references

publication date

4 June 2012

1 reference

Journal of Clinical Oncology

12 August 2017

1 reference

12 August 2017

30

1 reference

12 August 2017

21

1 reference

12 August 2017

2615-2623

1 reference

describes a project that uses

12 August 2017

Cytoscape

1 reference

9 June 2022

https://europepmc.org/search?query=(METHODS:'Cytoscape')

based on heuristic

inferred from PubMed Central ID database lookup

cites work

Deconstructing the molecular portraits of breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3413275

Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3413275

Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3413275

Management of advanced breast cancer with the epothilone B analog, ixabepilone

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3413275

In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3413275

Gene-expression signatures in breast cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3413275

Supervised risk predictor of breast cancer based on intrinsic subtypes

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3413275

Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3413275

Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3413275

EGFR associated expression profiles vary with breast tumor subtype

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3413275

Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3413275

Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3413275

The molecular portraits of breast tumors are conserved across microarray platforms

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3413275

Circulating tumor cells, disease progression, and survival in metastatic breast cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3413275

Platinum-based chemotherapy in metastatic breast cancer: current status.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3413275

Minimizing predictability while retaining balance through the use of less restrictive randomization procedures

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3413275

Breast cancer classification and prognosis based on gene expression profiles from a population-based study

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3413275

Repeated observation of breast tumor subtypes in independent gene expression data sets

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3413275

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3413275

Molecular portraits of human breast tumours

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3413275

The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3413275

Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3413275

Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3413275

Optimal two-stage designs for phase II clinical trials

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3413275

Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3413275

Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3413275

HER2 and Response to Paclitaxel in Node-Positive Breast Cancer

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3413275

High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history

5 December 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22665533

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1200/JCO.2010.34.5579

1 reference

12 August 2017

1 reference

12 August 2017

PubMed publication ID

22665533

1 reference